Search for: "Lange v. Andrews"
Results 41 - 60
of 131
Sort by Relevance
|
Sort by Date
24 Jul 2023, 1:41 am
Comment The Court of Appeal noted that it was unfortunate that the trial judge was not referred to Hallen v Brabantia. [read post]
16 Jul 2023, 11:56 pm
More from our authors: Vissers Annotated European Patent Convention 2023 Edition by Kaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge€ 105 Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 Patent Litigation Through the Unified Patent Court… [read post]
9 Jul 2023, 10:59 am
In Jones Lange LaSalle Brokerage, Inc. v. 1441 L Associates, LLC, No. 22-046, JLL represented both parties to an agreement to lease property in northwest Washington, DC. [read post]
6 Jul 2023, 2:55 am
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
2 Jul 2023, 1:37 am
Indicated entitlement to be a UPC representative More from our authors: Vissers Annotated European Patent Convention 2023 Edition by Kaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge€ 105 Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 … [read post]
13 Jun 2023, 3:36 am
The judgment is also interesting because it is the first time the court has really focused on the question of interest on past licensing fees (interest on past licensing fees is in issue in InterDigital v Lenovo, but the question of whether it is payable and in what amount was adjourned to a later hearing). [read post]
29 May 2023, 11:43 am
These provisions, placed today in Chapter V of the UPCA, include the definition of the patent’s owner prerogatives to prevent the direct and indirect use of the invention (Art. 25 and 26), the list of limitations concerning the scope of patent protection, including inter alia, acts done privately or for experimental purposes, the use of biological material for the purpose of breeding, discovering and developing other plant varieties (Art. 27), the condition of the right for prior use… [read post]
15 May 2023, 1:47 am
More from our authors: Vissers Annotated European Patent Convention 2023 Edition by Kaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge€ 105 Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 The Digital Economy and International Trade:… [read post]
11 May 2023, 2:21 am
On 4 May 2023, a mere two weeks after the conclusion of the hearing, the Court of Appeal handed down its decision in Sandoz and Teva v BMS. [read post]
4 May 2023, 7:48 am
In an earlier post I explained the issues that the proposed EU Regulation on SEPs intends to address, and why neither the market nor the courts solve them. [read post]
3 May 2023, 6:16 am
His Honour Judge Hacon handed down judgment in AutoStore v Ocado on 30 March 2023. [read post]
2 May 2023, 7:49 am
The only contentions of error the inventor made were issues of claim construction, which he forfeited by not raising them at the appropriate time during the inter partes review proceeding (Driessen v. [read post]
27 Apr 2023, 9:22 am
In this regard, in its judgment of 12 December 2013 (case C-493/12, Eli Lilly v Human Genome Sciences), the CJEU made the following observations: “30. [read post]
19 Apr 2023, 12:45 am
It is superfluous for cases such as Ericsson v Apple, costly and lengthy for the litigants, and clogs the court system. [read post]
8 Apr 2023, 3:50 am
More from our authors: Vissers Annotated European Patent Convention 2022 Edition by Kaisa Suominen, Peter de Lange, Andrew Rudge€ 105 Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 The Digital Economy and International Trade: Transnational Data… [read post]
6 Apr 2023, 6:38 am
The judge reviewed the national case law on selections/deletions from multiple lists (Merck v Shionogi [2016] EWHC 2989 (Pat), Nokia v IPCom [2012] EWCA Civ 567 and GlaxoSmithKline v Wyeth [2016] EWHC 1045 (Pat)) and the EPO cases reviewed therein and in the EPO Case Law Book. [read post]
29 Mar 2023, 2:50 am
The most famous decision might be the UK Supreme Court’s Ruling in Warner-Lambert Company LLC v Generics (UK) Ltd, which was reported on this blog here. [read post]
27 Mar 2023, 8:18 am
On 16 March 2022, the High Court of England and Wales handed down its judgment following the FRAND trial in InterDigital v Lenovo. [read post]
27 Mar 2023, 8:18 am
On 16 March 2023, the High Court of England and Wales handed down its judgment following the FRAND trial in InterDigital v Lenovo. [read post]
23 Mar 2023, 5:32 am
As an example, it can be a sign of infringement if the marketing strategy induces doctors to prescribe the generic for the omitted therapeutic indication (GlaxoSmithKline v. [read post]